Creo Medical Group (LON:CREO) Shares Up 4.1% – Should You Buy?

Shares of Creo Medical Group PLC (LON:CREO) rose 4.1% during trading on Monday . The stock traded as high as GBX 13.40 ($0.18) and last traded at GBX 13.40 ($0.18). Approximately 545,725 shares traded hands during trading, a decline of 57% from the average daily volume of 1,261,216 shares. The stock had previously closed at GBX 12.88 ($0.17).

Creo Medical Group Stock Performance

The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The firm has a market capitalization of £54.17 million, a P/E ratio of -2.12 and a beta of 0.86. The business’s 50 day simple moving average is GBX 12.94 and its two-hundred day simple moving average is GBX 14.30.

Creo Medical Group (LON:CREO) last posted its quarterly earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) EPS for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative return on equity of 41.79%. Sell-side analysts anticipate that Creo Medical Group PLC will post -10.0800005 EPS for the current fiscal year.

Insider Activity at Creo Medical Group

In other Creo Medical Group news, insider Kevin Crofton acquired 701,750 shares of Creo Medical Group stock in a transaction that occurred on Friday, May 30th. The stock was bought at an average cost of GBX 16 ($0.21) per share, for a total transaction of £112,280 ($150,751.88). 22.43% of the stock is owned by company insiders.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.